HK1116803A1 - Novel anti-plgf antibody - Google Patents
Novel anti-plgf antibodyInfo
- Publication number
- HK1116803A1 HK1116803A1 HK08102805.3A HK08102805A HK1116803A1 HK 1116803 A1 HK1116803 A1 HK 1116803A1 HK 08102805 A HK08102805 A HK 08102805A HK 1116803 A1 HK1116803 A1 HK 1116803A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- novel anti
- plgf antibody
- fragments
- plgf
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66476805P | 2005-03-24 | 2005-03-24 | |
PCT/BE2006/000023 WO2006099698A2 (en) | 2005-03-24 | 2006-03-24 | Novel anti-plgf antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1116803A1 true HK1116803A1 (en) | 2009-01-02 |
Family
ID=36928446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08102805.3A HK1116803A1 (en) | 2005-03-24 | 2008-03-11 | Novel anti-plgf antibody |
Country Status (27)
Country | Link |
---|---|
US (3) | US7875704B2 (de) |
EP (2) | EP2447281B1 (de) |
JP (2) | JP5164829B2 (de) |
KR (1) | KR101314014B1 (de) |
CN (1) | CN101184776B (de) |
AT (1) | ATE549358T1 (de) |
AU (2) | AU2006227571B8 (de) |
BR (1) | BRPI0609151B8 (de) |
CA (1) | CA2601267C (de) |
CY (1) | CY1113224T1 (de) |
DK (1) | DK1869085T3 (de) |
EA (1) | EA013970B1 (de) |
ES (2) | ES2565481T3 (de) |
HK (1) | HK1116803A1 (de) |
HR (1) | HRP20120477T1 (de) |
IL (1) | IL185754A (de) |
ME (1) | ME01446B (de) |
MX (1) | MX2007011735A (de) |
NO (1) | NO341877B1 (de) |
NZ (1) | NZ561763A (de) |
PL (1) | PL1869085T3 (de) |
PT (1) | PT1869085E (de) |
RS (1) | RS52372B (de) |
SI (1) | SI1869085T1 (de) |
UA (1) | UA94707C2 (de) |
WO (1) | WO2006099698A2 (de) |
ZA (1) | ZA200707258B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001265953B2 (en) * | 2000-05-12 | 2005-09-29 | D. Collen Research Foundation Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
JP5164829B2 (ja) | 2005-03-24 | 2013-03-21 | トロンボジェニクス・ナムローゼ・フエンノートシャップ | 新規な抗plgf抗体 |
CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
EP3002299A1 (de) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual-variable- domain-immunglobuline und ihre verwendungen |
KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2352761B1 (de) | 2008-10-02 | 2016-06-22 | Vib Vzw | Inhibierung von plgf zur behandlung von philadelphia chromosom positiver leukämie |
CA2746120A1 (en) * | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
CN102458459A (zh) * | 2009-05-01 | 2012-05-16 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
NZ598929A (en) | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
CN102666875A (zh) * | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2789564C (en) | 2010-03-10 | 2019-08-13 | F. Hoffmann-La Roche Ag | Method for purifying immunoglobulin solutions |
BR112012033423A2 (pt) * | 2010-07-19 | 2016-10-25 | Hoffmann La Roche | métodos para melhorar a eficácia do tratamento de um regime de quimioterapia e in vitro, usos de bevacizumab e de sondas específicas, kit e uso de um polipeptídeo |
BR112013002578A2 (pt) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
ES2628321T3 (es) | 2011-12-01 | 2017-08-02 | Thrombogenics N.V. | Mejora del resultado de una trabeculectomía |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
MY194330A (en) | 2012-11-01 | 2022-11-28 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
WO2014099931A1 (en) | 2012-12-18 | 2014-06-26 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CN104930353B (zh) * | 2015-07-10 | 2017-08-15 | 浙江大学 | 一种城市供水管网的调压减漏评估系统 |
US20190031762A1 (en) | 2016-03-10 | 2019-01-31 | Thrombogenics Nv | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
EP3606555A4 (de) * | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon |
CN109134650A (zh) * | 2018-09-10 | 2019-01-04 | 宁波奥丞生物科技有限公司 | 抗人plgf单克隆抗体的制备方法 |
US20220220197A1 (en) | 2019-05-28 | 2022-07-14 | Vib Vzw | Cancer Treatment by Targeting Plexins in the Immune Compartment |
US20220228116A1 (en) | 2019-05-28 | 2022-07-21 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
WO2020260595A1 (en) | 2019-06-26 | 2020-12-30 | Oncurious Nv | Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent |
EP3936868A1 (de) | 2020-07-10 | 2022-01-12 | Charité - Universitätsmedizin Berlin | Verhältnis zwischen plgf und sflt1, das prädiktiv für die neurale invasion bei patienten mit pankreaskrebs ist |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
GB2616177A (en) * | 2020-11-10 | 2023-08-30 | Ningbo Aucheer Biotechnology Co Ltd | Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof |
CN112358546B (zh) * | 2020-11-10 | 2022-04-01 | 宁波奥丞生物科技有限公司 | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用 |
JP2023554520A (ja) | 2020-12-22 | 2023-12-27 | コビオレス エヌヴイ | テトラペプチド部分を含む化合物 |
CN113999310A (zh) * | 2020-12-30 | 2022-02-01 | 江苏普若维生物技术有限责任公司 | 一种plgf单克隆抗体、试剂盒、其制备方法和应用 |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
EP4294407A1 (de) | 2021-02-17 | 2023-12-27 | Vib Vzw | Hemmung von slc4a4 bei der behandlung von krebs |
WO2023118294A1 (en) | 2021-12-22 | 2023-06-29 | Vib Vzw | Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis |
WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
JP3353209B2 (ja) | 1992-04-03 | 2002-12-03 | ジェネンテク,インコーポレイテッド | αvβ3インテグリンに対する抗体 |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
NZ320006A (en) | 1995-10-23 | 2001-12-21 | Meditech Res Ltd | An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction |
EP0928203B1 (de) | 1996-09-24 | 2006-10-25 | Merck & Co., Inc. | Verbindungen zur hemmung der angiogenese durch gentherapie |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
GB9723780D0 (en) | 1997-11-12 | 1998-01-07 | Univ Manchester | Regulation of ocular angiogenesis |
JP4532733B2 (ja) | 1998-03-17 | 2010-08-25 | ジェネンテック, インコーポレイテッド | Vegfおよびbmp1と相同なポリペプチド群 |
JPH11302193A (ja) * | 1998-04-22 | 1999-11-02 | Toagosei Co Ltd | 血管新生阻害剤 |
CA2332336A1 (en) | 1998-05-26 | 1999-12-02 | Erik Depla | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
JP2001086982A (ja) | 1999-07-16 | 2001-04-03 | Shunpei Niida | 骨吸収調節薬 |
WO2001057067A1 (en) | 2000-02-04 | 2001-08-09 | Supratek Pharma Inc. | Ligand for vascular endothelial growth factor receptor |
AU2001265953B2 (en) * | 2000-05-12 | 2005-09-29 | D. Collen Research Foundation Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
JP2005515157A (ja) * | 2001-05-25 | 2005-05-26 | トマス ジェファソン ユニバーシティ | 多様な治療様式のための主成分としての選択的スプライスフォーム |
US7139817B1 (en) * | 2001-06-12 | 2006-11-21 | Network Appliance, Inc. | Managing configuration information for multiple devices |
AU2002316305A1 (en) | 2001-06-20 | 2003-01-08 | Vlaams Interuniversitair Institut Voor Biotechnologie | Method of treating atherosclerosis and other inflammatory diseases |
WO2003063904A2 (en) | 2002-01-29 | 2003-08-07 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Tissue adhesion formation control |
CA2486270C (en) | 2002-06-05 | 2015-07-28 | Genentech, Inc. | Vegfr modulating agents and methods for liver growth and liver protection |
AU2003251729A1 (en) | 2002-06-28 | 2004-01-19 | K.U.Leuven Research & Development | Use of antibodies against flt-1 for the treatment of osteoporosis |
KR20050088998A (ko) * | 2002-11-08 | 2005-09-07 | 프리마겐 홀딩 비.브이. | 2 이상의 핵산서열 간의 비의 정량화 방법 |
EP1610806A4 (de) * | 2003-03-10 | 2006-04-19 | Callisto Pharmaceuticals Inc | Verfahren zur behandlung von krebs mit azaspiran-zusammensetzungen |
US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
JP5164829B2 (ja) | 2005-03-24 | 2013-03-21 | トロンボジェニクス・ナムローゼ・フエンノートシャップ | 新規な抗plgf抗体 |
WO2007003609A1 (en) | 2005-06-30 | 2007-01-11 | Vib Vzw | Treatment of liver cirrhosis and its complications |
EP2352761B1 (de) | 2008-10-02 | 2016-06-22 | Vib Vzw | Inhibierung von plgf zur behandlung von philadelphia chromosom positiver leukämie |
-
2006
- 2006-03-24 JP JP2008502194A patent/JP5164829B2/ja not_active Expired - Fee Related
- 2006-03-24 WO PCT/BE2006/000023 patent/WO2006099698A2/en active Application Filing
- 2006-03-24 RS RS20120249A patent/RS52372B/en unknown
- 2006-03-24 PL PL06721544T patent/PL1869085T3/pl unknown
- 2006-03-24 DK DK06721544.2T patent/DK1869085T3/da active
- 2006-03-24 SI SI200631343T patent/SI1869085T1/sl unknown
- 2006-03-24 US US11/909,604 patent/US7875704B2/en not_active Expired - Fee Related
- 2006-03-24 PT PT06721544T patent/PT1869085E/pt unknown
- 2006-03-24 EP EP11160897.2A patent/EP2447281B1/de not_active Not-in-force
- 2006-03-24 AU AU2006227571A patent/AU2006227571B8/en not_active Ceased
- 2006-03-24 KR KR1020077024317A patent/KR101314014B1/ko active IP Right Grant
- 2006-03-24 AT AT06721544T patent/ATE549358T1/de active
- 2006-03-24 ZA ZA200707258A patent/ZA200707258B/xx unknown
- 2006-03-24 ME MEP-2012-73A patent/ME01446B/me unknown
- 2006-03-24 UA UAA200711730A patent/UA94707C2/ru unknown
- 2006-03-24 EA EA200702064A patent/EA013970B1/ru not_active IP Right Cessation
- 2006-03-24 MX MX2007011735A patent/MX2007011735A/es active IP Right Grant
- 2006-03-24 NZ NZ561763A patent/NZ561763A/en unknown
- 2006-03-24 CA CA2601267A patent/CA2601267C/en not_active Expired - Fee Related
- 2006-03-24 BR BRPI0609151A patent/BRPI0609151B8/pt not_active IP Right Cessation
- 2006-03-24 ES ES11160897.2T patent/ES2565481T3/es active Active
- 2006-03-24 ES ES06721544T patent/ES2384110T3/es active Active
- 2006-03-24 CN CN2006800093279A patent/CN101184776B/zh not_active Expired - Fee Related
- 2006-03-24 EP EP06721544A patent/EP1869085B1/de active Active
-
2007
- 2007-09-05 IL IL185754A patent/IL185754A/en active IP Right Grant
- 2007-09-10 NO NO20074563A patent/NO341877B1/no not_active IP Right Cessation
-
2008
- 2008-03-11 HK HK08102805.3A patent/HK1116803A1/xx not_active IP Right Cessation
-
2010
- 2010-12-20 US US12/973,155 patent/US8758748B2/en active Active
-
2011
- 2011-03-23 AU AU2011201340A patent/AU2011201340B2/en not_active Ceased
-
2012
- 2012-02-01 JP JP2012019698A patent/JP2012136522A/ja active Pending
- 2012-06-06 HR HRP20120477TT patent/HRP20120477T1/hr unknown
- 2012-06-12 CY CY20121100535T patent/CY1113224T1/el unknown
-
2014
- 2014-02-03 US US14/170,997 patent/US9085617B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1116803A1 (en) | Novel anti-plgf antibody | |
HRP20181565T1 (hr) | Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
ATE461220T1 (de) | Anti-egfr-antikörper | |
WO2005003169A3 (en) | Modified antibody fab fragments | |
WO2003034903A3 (en) | Psma antibodies and protein multimers | |
PL2097453T3 (pl) | Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) | |
ATE545657T1 (de) | Tgf-beta antikörper | |
EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
EP1411962A4 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
SG162829A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
UA94245C2 (en) | Anti-il-17 antibodies | |
CY1115979T1 (el) | Αντισωματα κατα της μυοστατινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210329 |